Botulinum Toxin A to sialorrhea treatment: a systematic review
DOI:
https://doi.org/10.5935/0104-7795.20130024Keywords:
Botulinum Toxins Type A, Sialorrhea, RehabilitationAbstract
Objective: To systematize scientific evidences about the efficacy of botulinum toxin type A for treatment of sialorrhea. Method: A bibliographic search was performed on the databases PubMed Central Journals and Allergan Product Literature - botulinum toxin (APL) encompassing articles published on the last 10 years containing the keywords: “sialorrhea”, “botulinum toxin”, “treatment”, “hypersalivation”, “drooling”. The methodological quality of these articles was evaluated using the Jadad scale. Results: Four randomized, double-blind clinical trials were selected. The selected studies demonstrate that the application of botulinum toxin may satisfactorily reduce sialorrhea and its consequences, and it does not produce important adverse side effects. Therefore, treatment with botulinum toxin type A may be a possible therapeutic option in patients with sialorrhea. Conclusion: More studies with adequate quality are required form a definitive conclusion about the efficacy and safety of this procedure in patients with sialorrhea.
Downloads
References
Lakraj AA, Moghimi N, Jabbari B. Sialorrhea: anatomy, pathophysiology and treatment with emphasis on the role of botulinum toxins. Toxins (Basel). 2013;5(5):1010-31. DOI: http://dx.doi.org/10.3390/toxins5051010
Scully C, Limeres J, Gleeson M, Tomás I, Diz P. Drooling. J Oral Pathol Med. 2009;38(4):321-7. DOI: http://dx.doi.org/10.1111/j.1600-0714.2008.00727.x
Vashishta R, Nguyen SA, White DR, Gillespie MB. Botulinum toxin for the treatment of sialorrhea: a meta-analysis. Otolaryngol Head Neck Surg. 2013;148(2):191-6. DOI: http://dx.doi.org/10.1177/0194599812465059
Jadad AR, Moore RA, Carroll D, Jenkinson C, Reynolds DJ, Gavaghan DJ, et al. Assessing the quality of reports of randomized clinical trials: is blinding necessary? Control Clin Trials. 1996;17(1):1-12. DOI: http://dx.doi.org/10.1016/0197-2456(95)00134-4
Wu KP, Ke JY, Chen CY, Chen CL, Chou MY, Pei YC. Botulinum toxin type A on oral health in treating sialorrhea in children with cerebral palsy: a randomized, double-blind, placebo-controlled study. J Child Neurol. 2011;26(7):838-43. DOI: http://dx.doi.org/10.1177/0883073810395391
Alrefai AH, Aburahma SK, Khader YS. Treatment of sialorrhea in children with cerebral palsy: a double-blind placebo controlled trial. Clin Neurol Neurosurg. 2009;111(1):79-82. DOI: http://dx.doi.org/10.1016/j.clineuro.2008.09.001
Reid SM, Johnstone BR, Westbury C, Rawicki B, Reddihough DS. Randomized trial of botulinum toxin injections into the salivary glands to reduce drooling in children with neurological disorders. Dev Med Child Neurol. 2008;50(2):123-8.
Lagalla G, Millevolte M, Capecci M, Provinciali L, Ceravolo MG. Long-lasting benefits of botulinum toxin type B in Parkinson's disease-related drooling. J Neurol. 2009;256(4):563-7. DOI: http://dx.doi.org/10.1007/s00415-009-0085-1
Manrique D. Aplicaçao de toxina botulínica tipo A para reduzir a saliva em pacientes com esclerose lateral amiotrófica. Rev Bras Otorrinolaringol. 2005;71(5):566-9. DOI: http://dx.doi.org/10.1590/S0034-72992005000500004
Borodic GE, Acquadro M, Johnson EA. Botulinum toxin therapy for pain and inflammatory disorders: mechanisms and therapeutic effects. Expert Opin Investig Drugs. 2001;10(8):1531-44. DOI: http://dx.doi.org/10.1517/13543784.10.8.1531
Lee SJ, McCall WD Jr, Kim YK, Chung SC, Chung JW. Effect of botulinum toxin injection on nocturnal bruxism: a randomized controlled trial. Am J Phys Med Rehabil. 2010;89(1):16-23. DOI: http://dx.doi.org/10.1097/PHM.0b013e3181bc0c78
Balbinot LF. Toxina Botulínica do tipo A. In: Maciel RN. Bruxismo. Porto Alegre: Artes Médicas; 2010. p. 525-34.
Guidubaldi A, Fasano A, Ialongo T, Piano C, Pompili M, Mascianà R, et al. Botulinum toxin A versus B in sialorrhea: a prospective, randomized, double-blind, crossover pilot study in patients with amyotrophic lateral sclerosis or Parkinson's disease. Mov Disord. 2011;26(2):313-9. DOI: http://dx.doi.org/10.1002/mds.23473
Ellies M, Laskawi R, Rohrbach-Volland S, Arglebe C, Beuche W. Botulinum toxin to reduce saliva flow: selected indications for ultrasound-guided toxin application into salivary glands. Laryngoscope. 2002;112(1):82-6. DOI: http://dx.doi.org/10.1097/00005537-200201000-00015
Fuster Torres MA, Berini Aytés L, Gay Escoda C. Salivary gland application of botulinum toxin for the treatment of sialorrhea. Med Oral Patol Oral Cir Bucal. 2007;12(7):E511-7.
Jongerius PH, Rotteveel JJ, van Limbeek J, Gabreëls FJ, van Hulst K, van den Hoogen FJ. Botulinum toxin effect on salivary flow rate in children with cerebral palsy. Neurology. 2004;63(8):1371-5. DOI: http://dx.doi.org/10.1212/01.WNL.0000142040.57474.A6
Adair B, Graham HK. Systemic adverse events following injections of Botulinum Toxin A (BoNT-A) in children with cerebral palsy. Dev Med Child Neurol. 2009;51(Suppl 2):54-5.
Rodwell K, Edwards P, Ware RS, Boyd R. Salivary gland botulinum toxin injections for drooling in children with cerebral palsy and neurodevelopmental disability: a systematic review. Dev Med Child Neurol. 2012;54(11):977-87. DOI: http://dx.doi.org/10.1111/j.1469-8749.2012.04370.x
U.S. Food and Drug Administration. Early communication about an ongoing safety review Botox and Botox Cosmetic (botulinum toxin type A) and Myobloc (botulinum toxin type B). Plast Surg Nurs. 2008;28(3):150-1.
Downloads
Published
Issue
Section
License
Copyright (c) 2013 Acta Fisiátrica
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.
